Field Effectiveness of the Oral and the Intrauterine Methods of Contraception

Field Effectiveness of the Oral and the Intrauterine Methods of Contraception PDF Author: M. Francoise Hall
Publisher:
ISBN:
Category :
Languages : en
Pages : 17

Get Book Here

Book Description

Field Effectiveness of the Oral and the Intrauterine Methods of Contraception

Field Effectiveness of the Oral and the Intrauterine Methods of Contraception PDF Author: M. Francoise Hall
Publisher:
ISBN:
Category :
Languages : en
Pages : 17

Get Book Here

Book Description


Mechanism of Action Safety and Efficacy of Intrauterine Devices

Mechanism of Action Safety and Efficacy of Intrauterine Devices PDF Author: WHO Scientific Group on Mechanism of Action, Safety, and Efficacy of Intrauterine Devices
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 96

Get Book Here

Book Description
The mechanism of action, safety, and efficacy of IUDs were reviewed by a WHO Scientific Group in 1986. The Scientific Group concluded that the IUD should continue to be supported, in both developed and developing countries, as a safe, reliable method of fertility regulation. The newer copper-releasing devices are comparable to oral contraceptives in terms of safety and efficacy. When compared to women who use other reversible methods of contraception, IUD users have the lowest mortality resulting from deaths directly attributable to those methods or to the consequences of unwanted pregnancy. In the past decade, research has concentrated on the development of new devices that have both higher continuation rates and lower rates of expulsion and removal for bleeding abnormalities. An important recent concern has been the possible increased risk of pelvic inflammatory disease (PID) and subsequent tubal infertility associated with IUD use. However, it now appears that methodological problems have caused the IUD-associated risk of PID to be overestimated. The increased risk with IUDs seems to be limited to the 1st 4 months of use. No increased risk of tubal infertility has been found among IUD users in stable, monogamous sexual relationships. The use of a copper IUD after the 1st pregnancy is not associated with secondary infertility due to tubal disease. Finally, the newer copper IUDs have low rates of ectopic pregnancy.

Field effectivenesss [!] of the oral and the intrauterine methods of contraception

Field effectivenesss [!] of the oral and the intrauterine methods of contraception PDF Author: M.-Françoise Hall
Publisher:
ISBN:
Category :
Languages : en
Pages : 17

Get Book Here

Book Description


Selected Practice Recommendations for Contraceptive Use

Selected Practice Recommendations for Contraceptive Use PDF Author: World Health Organization. Reproductive Health and Research
Publisher: World Health Organization
ISBN: 9241562846
Category : Medical
Languages : en
Pages : 144

Get Book Here

Book Description
This document is one of two evidence-based cornerstones of the World Health Organization's (WHO) new initiative to develop and implement evidence-based guidelines for family planning. The first cornerstone, the Medical eligibility criteria for contraceptive use (third edition) published in 2004, provides guidance for who can use contraceptive methods safely. This document, the Selected practice recommendations for contraceptive use (second edition), provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. The recommendations contained in this document are the product of a process that culminated in an expert Working Group meeting held at the World Health Organization, Geneva, 13-16 April 2004.

Contraceptive Use by Method 2019

Contraceptive Use by Method 2019 PDF Author: United Nations
Publisher:
ISBN: 9789211483291
Category : Political Science
Languages : en
Pages : 25

Get Book Here

Book Description
This data booklet highlights estimates of the prevalence of individual contraceptive methods based on the World Contraceptive Use 2019 (which draws from 1,247 surveys for 195 countries or areas of the world) and additional tabulations obtained from microdata sets and survey reports. The estimates are presented for female and male sterilisation, intrauterine device (IUD), implant, injectable, pill, male condom, withdrawal, rhythm and other methods combined.

Contraception and Reproduction

Contraception and Reproduction PDF Author: Working Group on the Health Consequences of Contraceptive Use and Controlled Fertility
Publisher:
ISBN:
Category :
Languages : es
Pages : 0

Get Book Here

Book Description
Se estudian las consecuencias sanitarias de los diferentes patrones reproductivos en la salud de la mujer y de los niños. Tambien se evaluan el riesgo y los beneficios de los diferentes metodos anticonceptivos, aunque algunos de los datos en los que se basa son de paises desarrollados, el nucleo central del informe son los paises en desarrollo.

Medical Eligibility Criteria for Contraceptive Use

Medical Eligibility Criteria for Contraceptive Use PDF Author:
Publisher: World Health Organization
ISBN: 9241563885
Category : Business & Economics
Languages : en
Pages : 130

Get Book Here

Book Description
Medical Eligibility Criteria for Contraceptive Use reviews the medical eligibility criteria for use of contraception, offering guidance on the safety and use of different methods for women and men with specific characteristics or known medical conditions. The recommendations are based on systematic reviews of available clinical and epidemiological research. It is a companion guideline to Selected Practice Recommendations for Contraceptive Use. Together, these documents are intended to be used by policy-makers, program managers, and the scientific community to support national programs in the preparation of service delivery guidelines. The fourth edition of this useful resource supersedes previous editions, and has been fully updated and expanded. It includes over 86 new recommendations and 165 updates to recommendations in the previous edition. Guidance for populations with special needs is now provided, and a new annex details evidence on drug interactions from concomitant use of antiretroviral therapies and hormonal contraceptives. To assist users familiar with the third edition, new and updated recommendations are highlighted. Everyone involved in providing family planning services and contraception should have the fourth edition of Medical Eligibility Criteria for Contraceptive Use at hand.

The Billings Method

The Billings Method PDF Author: Evelyn Billings
Publisher: Gracewing Publishing
ISBN: 9780852442623
Category : Contraception
Languages : es
Pages : 268

Get Book Here

Book Description


Handbook of Gynecology

Handbook of Gynecology PDF Author: Donna Shoupe
Publisher: Springer Nature
ISBN: 3031148819
Category : Medical
Languages : en
Pages : 1295

Get Book Here

Book Description
This book is a comprehensive, up-to-date reference on general and subspecialty gynecology. Covering all aspects of gynecology commonly encountered in day-to-day practice, this exhaustive and fully updated new edition provides a practical, one-stop reference work for clinicians working in the field. This carefully-designed volume includes ten sections, beginning with comprehensive coverage of office-based gynecology, and continuing on to present disease processes and management information by patient age group. Each chapter includes background information, current recommendations for screening, diagnostic criteria, common and uncommon associated problems, approach to diagnosis, summary of treatment options, and an overview of ICD-10 codes for specific diagnoses. Importantly, many areas that are covered in the handbook as subspecialty problems are pertinent and important information to many of the general practitioners who handle and develop some expertise in these areas. These include ovulation induction, medical management of incontinence, management of abnormal Pap smears, and work-up of abnormal bleeding. The handbook concludes with an easy-to-navigate presentation of minimally-invasive operations, surgical procedures, neoplasms, and pathology. Advantages and risks associated with management of particular diseases are covered, along with multiple tips for avoiding complications. This second edition is fully updated. With extensive updates on cervical cancer screening, pelvic organ prolapse, and more, many chapters will be completely rewritten to reflect the latest guidelines, procedures, and methods of care in women’s health. The text additionally includes two new chapters, covering the impact of COVID on gynecology care, and the work-up and surgical management of chronic pelvic pain. This is an ideal guide for practicing gynecologists, family and internal medicine physicians, physician assistants, nurse practitioners, fellows, residents, medical students, and all women’s health care providers.

Hormonal Contraception and Post-menopausal Hormonal Therapy

Hormonal Contraception and Post-menopausal Hormonal Therapy PDF Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN:
Category : Medical
Languages : en
Pages : 692

Get Book Here

Book Description
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.